On May 13, 2025, GSK plc announced that it will stop the development of belrestotug due to unmet efficacy criteria from recent phase 2 studies. This decision marks the end of its collaboration with iTeos Therapeutics for this drug.
AI Assistant
GSK PLC
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.